AbbVie/Allergan merger cleared in EU with brazikumab sell-of...

AbbVie and Allergan’s $63 billion merger has been cleared by European regulators, who have approved the sell-off of pipeline gastrointestinal autoimmune diseases drug brazikumab to AstraZen

AZ buys back rights to Crohn's candidate from Allergan, ahea...

Allergan is selling rights to its Crohn’s disease drug brazikumab back to AstraZeneca in a move to satisfy regulators ahead of its merger with AbbVie.

J&J gets Stelara okay in Europe for ulcerative colitis

Allergan says it will shed two drugs as AbbVie takeover loom...

Takeda's Entyvio outperforms AbbVie's Humira in GI trial

Takeda has announced results from its gastro drug Entyvio, showing that it largely outperformed the industry standard – AbbVie’s Humira – in severely active ulcerative colitis.

New data sets up potential new gastro use for J&J's Stelara

Janssen’s Stelara has shown positive results in an ulcerative colitis (UC) trial, setting up a potential new indication for the inflammatory diseases drug.